Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Authors
Keywords
Atherosclerotic cardiovascular disease (ASCVD), Major atherosclerotic cardiovascular risk (MACE), Extreme risk, Very high risk, Multi-morbidities, Secondary prevention
Journal
Current Diabetes Reports
Volume 19, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-22
DOI
10.1007/s11892-019-1178-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2019) Scott M. Grundy et al. CIRCULATION
- Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
- (2019) Emelia J. Benjamin et al. CIRCULATION
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. ATHEROSCLEROSIS
- Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary SyndromesClinical Perspective
- (2016) David Nanchen et al. CIRCULATION
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study
- (2016) O A Alabas et al. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
- Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
- (2016) Sabina A. Murphy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
- (2016) Amit V. Khera et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 8. Cardiovascular Disease and Risk Management
- (2015) DIABETES CARE
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
- (2015) Terry A. Jacobson et al. Journal of Clinical Lipidology
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronary Artery Calcium Scanning
- (2015) Harvey S. Hecht JACC-Cardiovascular Imaging
- High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN
- (2014) Brian Stegman et al. DIABETES CARE
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease
- (2014) Peter P. Toth et al. Journal of Clinical Lipidology
- American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
- (2013) Paul Jellinger et al. Endocrine Practice
- An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
- (2013) Scott M. Grundy et al. Journal of Clinical Lipidology
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
- (2013) David C. Goff et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Is type 2 diabetes really a coronary heart disease risk equivalent?
- (2013) Christoph H. Saely et al. VASCULAR PHARMACOLOGY
- Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
- (2013) Alexandrios Briasoulis et al. Current Cardiology Reports
- Lifetime Risks of Cardiovascular Disease
- (2012) Jarett D. Berry et al. NEW ENGLAND JOURNAL OF MEDICINE
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
- (2011) Sidney C. Smith et al. CIRCULATION
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
- (2011) Allan D. Sniderman et al.
- Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
- (2011) Michael H. Davidson et al. Journal of Clinical Lipidology
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design
- (2010) David Preiss et al. AMERICAN HEART JOURNAL
- Diabetes and Coronary Heart Disease as Risk Factors for Mortality in Older Adults
- (2010) Mercedes R. Carnethon et al. AMERICAN JOURNAL OF MEDICINE
- Population based absolute and relative survival to 1 year of people with diabetes following a myocardial infarction: A cohort study using hospital admissions data
- (2010) Sinead Brophy et al. BMC PUBLIC HEALTH
- Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
- (2010) Deepak L. Bhatt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
- (2010) Philip Greenland et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Vascular Disease Burden and In-Hospital Outcomes Among Patients Undergoing Percutaneous Coronary Intervention in New York State
- (2009) Jeffrey S. Berger et al. Circulation-Cardiovascular Interventions
- Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome
- (2009) Steven Yakubov CURRENT MEDICAL RESEARCH AND OPINION
- Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes
- (2009) Sabina A. Murphy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
- (2009) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort
- (2009) FENG SUN et al. NEPHROLOGY
- Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
- (2009) Bengt C. Fellström et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk
- (2008) Tina Ken Schramm et al. CIRCULATION
- Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
- (2008) J. D. Brunzell et al. DIABETES CARE
- Is diabetes a coronary risk equivalent? Systematic review and meta-analysis
- (2008) U. Bulugahapitiya et al. DIABETIC MEDICINE
- Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling
- (2008) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
- (2008) GISSI-HF investigators LANCET
- Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
- (2008) Christopher J. O’Donnell et al. REVISTA ESPANOLA DE CARDIOLOGIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now